Virtual Library
Start Your Search
A. Kowalik
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-012 - The Development of EGFR Mutation Diagnostic Program for NSCLC Patients in Poland (2011-2014) (ID 2299)
09:30 - 09:30 | Author(s): A. Kowalik
- Abstract
Background:
Targeted therapy of non-small cell lung cancer necessitates fast and reliable molecular evaluation of tissue/cytologic samples within the routine diagnostic process. Here we present the dynamic development of the EGFR mutation screening program for NSCLC patients in Poland within the previous 4 years.
Methods:
In total, 287 samples were analysed for EGFR mutations in 2011 (13.3% positive, 3% unsuitable for diagnostics), 1249 (9.2%, 1.5%) in 2012, 2104 (10.1%, 1.9%) in 2013, 4307 (10.2%, 2.7%) in 2014. Adenocarcinomas were 85.9% in 2012, 93.2% in 2014. The percentage of NSCLC NOS materials decreased continuously (10% down to 5.3%). 72% of samples contained >50% of cancer cells, 15% - 20-50%, 5.5% - 10-20%, 7.5% - below 10%.
Results:
Between 2011-2014, 727 activating EGFR mutations were identified, including 5.8% in exon 18, 58.5% in exon 19, 35.7% in exon 21, and 83 in exon 20 (10%). Currently, all laboratories employ CE-IVD real-time PCR tests as diagnostic method of choice. Additionally, 3 labs use alternative diagnostic methods as well. Results are available within 48 hrs (1 lab), 3-5 days (3 labs), 6-7 days (2), >8 days (2). All centres participate in the external quality schemes.
Conclusion:
The diagnostic program provides fast and reliable diagnostics of EGFR mutation in NSCLC patients in Poland.
